Shares of Rubius Therapeutics Inc (NASDAQ:RUBY) saw strong trading volume on Friday . 2,834,366 shares were traded during mid-day trading, an increase of 825% from the previous session’s volume of 306,401 shares.The stock last traded at $16.29 and had previously closed at $15.58.
Several equities analysts have commented on the stock. Zacks Investment Research lowered shares of Rubius Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 15th. Morgan Stanley decreased their target price on shares of Rubius Therapeutics from $37.00 to $34.00 and set an “overweight” rating on the stock in a report on Wednesday, December 19th. Finally, ValuEngine lowered shares of Rubius Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 21st. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Rubius Therapeutics has a consensus rating of “Buy” and a consensus price target of $30.00.
The company has a quick ratio of 25.78, a current ratio of 25.78 and a debt-to-equity ratio of 0.06.
Institutional investors and hedge funds have recently bought and sold shares of the company. Legal & General Group Plc acquired a new stake in shares of Rubius Therapeutics in the 3rd quarter valued at approximately $44,000. New York State Common Retirement Fund acquired a new stake in shares of Rubius Therapeutics in the 4th quarter valued at approximately $116,000. Metropolitan Life Insurance Co. NY boosted its stake in shares of Rubius Therapeutics by 320.5% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 7,191 shares of the company’s stock valued at $116,000 after purchasing an additional 5,481 shares in the last quarter. LPL Financial LLC acquired a new stake in shares of Rubius Therapeutics in the 4th quarter valued at approximately $162,000. Finally, Bank of America Corp DE boosted its stake in shares of Rubius Therapeutics by 601.5% in the 4th quarter. Bank of America Corp DE now owns 11,048 shares of the company’s stock valued at $178,000 after purchasing an additional 9,473 shares in the last quarter. Institutional investors own 87.04% of the company’s stock.
WARNING: This piece of content was originally published by Zolmax and is the sole property of of Zolmax. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://zolmax.com/investing/rubius-therapeutics-ruby-sees-strong-trading-volume/2966120.html.
About Rubius Therapeutics (NASDAQ:RUBY)
Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria.
Featured Story: Cost of Equity
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.